Pivikto 200 mg Tablet

Product Description

Pivikto 200 mg tablet is a potent phosphatidylinositol 3-kinase (PI3K) inhibitor designed for the treatment of advanced hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer in both postmenopausal women and men. This innovative medication is particularly beneficial for patients who have specific mutations in the PIK3CA gene and have not responded to other hormonal therapies. When used in conjunction with fulvestrant, Pivikto can enhance treatment efficacy and provide new hope for those battling this challenging cancer type. Its essential for patients to discuss any existing health conditions and medications with their healthcare provider, as there are potential interactions and side effects associated with its use. Piviktos targeted action offers a modern approach to managing breast cancer, addressing a critical need in oncology. If you or a loved one are navigating advanced breast cancer, Pivikto could be a valuable option worth considering in your treatment plan. Always consult with your oncologist to ensure that Pivikto aligns with your specific medical needs and treatment goals.